● Lincomycin hydrochloride 2.5% (25 mg/mL) is a sterile ophthalmic solution; lincomycin is a lincosamide antibacterial agent used for topica
● Lincomycin hydrochloride 2.5% (25 mg/mL) is a sterile ophthalmic solution; lincomycin is a lincosamide antibacterial agent used for topical ocular administration [1][3]
● The solution is a clear, colourless liquid [1]
● Mechanism: lincomycin binds to the 50S ribosomal subunit of susceptible bacteria, blocks elongation of the peptide chain and inhibits bacterial protein synthesis; it is bacteriostatic, and at high concentrations it is also bactericidal against highly susceptible organisms [1]
● It has high antibacterial activity against Gram-positive bacteria such as staphylococci (including penicillin-resistant strains) and streptococci, with good activity against some Gram-negative bacteria [1]
● One mL contains 25 mg of lincomycin hydrochloride; a 0.4 mL single-dose unit contains about 10 mg [1][3]
● There is no cross-resistance with chloramphenicol or tetracyclines, partial cross-resistance with macrolides, and complete cross-resistance with clindamycin [1]
| Product Name | Lincomycin Hydrochloride Eye Drops 2.5% (25 mg/mL) 0.4 mL |
|---|---|
| Dosage Form | Ophthalmic |
| Strength | 2.5% (25 mg/mL) 0.4 mL |
| Standards | BP / ENTERPRISE |
| Packing | Customized per market requirement (bottle / blister / box) |
| Documents | COA, COPP, DMF, CTD Dossiers |
| MOQ | Contact us for MOQ and current stock |
Reference information summarised from WHO prescribing guidance. Expand each item below — clinical use must always follow the locally approved product insert.
Reference: WHO Model Formulary / WHO Model List of Essential Medicines. For professional reference only — clinical use must follow the locally approved product insert and national treatment guidelines.
Full batch testing and quality traceability under standard GMP workshops.
Sufficient stock on regular items, familiar with export logistics to 50+ countries.
COA, DMF, dossier and legalization documents for your market registration.
Every batch of Lincomycin Hydrochloride Eye Drops 2.5% (25 mg/mL) 0.4 mL ships with a Certificate of Analysis (COA). For market registration we provide COPP, DMF and CTD-format dossiers, plus legalisation support where your authority requires it.
MOQ and lead time for Lincomycin Hydrochloride Eye Drops 2.5% (25 mg/mL) 0.4 mL depend on strength, packaging and destination market. Send us your target market and annual volume — our export team confirms current stock, MOQ and lead time within 24 hours.
Yes. We offer OEM packaging and private-label production for Lincomycin Hydrochloride Eye Drops 2.5% (25 mg/mL) 0.4 mL, subject to the regulatory requirements of the destination market.
We have supplied ophthalmic products to 50+ countries across Africa, Southeast Asia, Latin America and the Middle East, with experience in ministry-of-health registration and international tenders.
Lincomycin Hydrochloride Eye Drops 2.5% (25 mg/mL) 0.4 mL is produced in China-GMP workshops (site re-inspected and passed in 2026), released only after full QC testing against BP / enterprise standards, with retained samples kept for one year beyond the product's expiry date.
Artemisine Medicines